# Janssen-Cilag Ltd. clinical trials: 35 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 35 trials with Janssen-Cilag Ltd. as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Janssen-Cilag Ltd.: 35 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/janssen-cilag-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 35
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 35, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 1, 2026 | NCT07851207 | A Study to Assess Guselkumab in Participants With Moderate-to-Severe Inflammatory Bowel Disease in Real Life Italian Setting | Janssen-Cilag Ltd. | Observational | Not yet recruiting | Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851207) |
| April 15, 2026 | NCT07532226 | A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants | Janssen-Cilag Ltd. | Observational | Recruiting | Arthritis, Psoriatic | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532226) |
| March 4, 2026 | NCT07449234 | A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis | Janssen-Cilag Ltd. | Observational | Terminated | Psoriasis | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07449234) |
| November 21, 2025 | NCT07242248 | A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United... | Janssen-Cilag Ltd. | Observational | Recruiting | Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn's Disease | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07242248) |
| June 25, 2024 | NCT06472778 | A Real-world Study in Participants With Smoldering Multiple Myeloma | Janssen-Cilag Ltd. | Observational | Completed | Smoldering Multiple Myeloma | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06472778) |
| May 10, 2024 | NCT06408935 | Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | Janssen-Cilag Ltd. | Phase 3 | Active not recruiting | Crohn's Disease | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06408935) |
| February 29, 2024 | NCT06285318 | A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of... | Janssen-Cilag Ltd. | Observational | Recruiting | Relapsed/Refractory Multiple Myeloma (RRMM) | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06285318) |
| June 13, 2023 | NCT05901649 | A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus... | Janssen-Cilag Ltd. | Observational | Completed | Metastatic Hormone-sensitive Prostate Cancer | 505 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05901649) |
| April 26, 2022 | NCT05347095 | A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | Janssen-Cilag Ltd. | Phase 3 | Active not recruiting | Fistulizing Crohns Disease, Perianal Crohns Disease | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05347095) |
| November 18, 2021 | NCT05125679 | Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis | Janssen-Cilag Ltd. | Phase 4 | Terminated | Psoriasis | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05125679) |
| April 2, 2021 | NCT04829669 | A Study of Participants With Moderate or Severe Major Depressive Disorder (MDD) Requiring Urgent Symptom Control in a Psychiatric Emergency | Janssen-Cilag Ltd. | Observational | Withdrawn | Depressive Disorder, Major | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04829669) |
| April 2, 2021 | NCT04829318 | A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray... | Janssen-Cilag Ltd. | Phase 4 | Completed | Depressive Disorder, Major | 183 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04829318) |
| January 18, 2020 | NCT04232228 | A Study to Evaluate the Impact of Care4Today® IBD, a Smart System to Facilitate the Management of Crohn's Disease by Patients and Health... | Janssen-Cilag Ltd. | Observational | Terminated | Crohn Disease | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04232228) |
| July 29, 2019 | NCT04035226 | A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior... | Janssen-Cilag Ltd. | Observational | Completed | Multiple Myeloma | 254 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04035226) |
| June 26, 2019 | NCT03998683 | A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis | Janssen-Cilag Ltd. | Phase 3 | Completed | Psoriasis | 117 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03998683) |
| May 20, 2019 | NCT03955900 | A Registry Study of Participants With Multiple Myeloma in Latin America | Janssen-Cilag Ltd. | Observational | Completed | Multiple Myeloma | 2,059 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03955900) |
| December 20, 2018 | NCT03782376 | A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's... | Janssen-Cilag Ltd. | Phase 3 | Completed | Crohn Disease | 215 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03782376) |
| April 12, 2018 | NCT03495973 | Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease | Janssen-Cilag Ltd. | Observational | Completed | Crohn Disease | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03495973) |
| February 7, 2018 | NCT03425591 | A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice | Janssen-Cilag Ltd. | Observational | Completed | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell | 508 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03425591) |
| December 14, 2017 | NCT03373253 | Treatment-Resistant Depression Cohort in Europe | Janssen-Cilag Ltd. | Observational | Completed | Depressive Disorder, Treatment-Resistant | 830 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03373253) |
| April 11, 2017 | NCT03107793 | Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab | Janssen-Cilag Ltd. | Phase 3 | Completed | Crohn Disease | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03107793) |
| August 22, 2016 | NCT02874560 | Evaluation of the Functional Remission Occurrence and Predictive Factors in Schizophrenia | Janssen-Cilag Ltd. | Observational | Completed | Schizophrenia | 364 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02874560) |
| May 16, 2016 | NCT02773394 | Study to Describe the Actual Situation of Hepatitis C Treatment in Brazil | Janssen-Cilag Ltd. | Observational | Completed | Hepatitis C Virus | 1,649 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02773394) |
| March 18, 2016 | NCT02713282 | A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the... | Janssen-Cilag Ltd. | Phase 3 | Completed | Schizophrenia | 306 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02713282) |
| March 18, 2016 | NCT02712463 | A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With Antipsychotics | Janssen-Cilag Ltd. | Observational | Completed | Schizophrenia | 310 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02712463) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 3 | 7 |
| Phase 4 | 8 |
| Observational | 20 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 24 |
| Terminated | 4 |
| Recruiting | 3 |
| Active not recruiting | 2 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Crohn Disease | 7 |
| Schizophrenia | 5 |
| Multiple Myeloma | 4 |
| Psoriasis | 3 |
| Depressive Disorder, Major | 2 |
| Depressive Disorder, Treatment-Resistant | 2 |
| Hepatitis C | 2 |
| Colitis, Ulcerative | 2 |
| Inflammatory Bowel Diseases | 2 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 |
| Learning Disabilities | 1 |
| Child Behavior Disorders | 1 |
| Mental Disorders | 1 |
| Arthritis, Psoriatic | 1 |
| Cancer Pain | 1 |
| Pain | 1 |
| Neoplasms | 1 |
| Helminthiasis | 1 |
| Amebiasis | 1 |
| Lymphoma, Mantle-Cell | 1 |
| Leukemia | 1 |
| Lymphoma | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Pain, Postoperative | 1 |
| Smoldering Multiple Myeloma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Immunodermatology practices in the United States](https://specstream.ai/data/businesses/immunodermatology-practices/united-states)
- [Hardware and fastener manufacturers in the United States](https://specstream.ai/data/businesses/hardware-and-fastener-manufacturers/united-states)
- [Food and beverage exporters in the United States](https://specstream.ai/data/businesses/food-and-beverage-exporters/united-states)
- [Estate planning law firms in the United States](https://specstream.ai/data/businesses/estate-planning-law-firms/united-states)
- [Dumpling restaurants in the United States](https://specstream.ai/data/businesses/dumpling-restaurants/united-states)
- [Court reporters in the United States](https://specstream.ai/data/businesses/court-reporters/united-states)
